Evidence for the involvement of descending pain-inhibitory mechanisms in the attenuation of cancer pain by carvacrol aided through a docking study

The present study evaluated the carvacrol (CARV) effect on hyperalgesia and nociception induced by sarcoma 180 (S180) in mice. Carvacrol treatment (12.5–50mg/kgs.c.) once daily for 15days was started 24h after injection of the sarcoma cells in the hind paw (s.c.). Mice were evaluated for mechanical...

Full description

Saved in:

Bibliographic Details
Published in:	Life sciences (1973) Vol. 116; no. 1; pp. 8 - 15
Main Authors:	Guimarães, Adriana G., Scotti, Luciana, Scotti, Marcus Tullius, Mendonça Júnior, Francisco J.B., Melo, Nayara S.R., Alves, Rafael S., De Lucca Júnior, Waldecy, Bezerra, Daniel P., Gelain, Daniel P., Quintans Júnior, Lucindo J.
Format:	Journal Article
Language:	English
Published:	Netherlands Elsevier Inc 22-10-2014
Subjects:	Analgesics - administration & dosage Analgesics - pharmacology Animals Cancer pain Carvacrol Dose-Response Relationship, Drug Hyperalgesia Hyperalgesia - drug therapy Hyperalgesia - etiology Interleukin-10 - metabolism Male Mice Molecular Docking Simulation Monoterpene Monoterpenes - administration & dosage Monoterpenes - pharmacology Muscimol - pharmacology Nociception Nociception - drug effects Pain - drug therapy Pain - etiology Periaqueductal Gray - drug effects Periaqueductal Gray - metabolism Receptors, GABA-A - metabolism Sarcoma 180 - complications Sarcoma 180 - pathology Spinal Cord - drug effects Spinal Cord - metabolism Nociception Morphine (PubChem CID: 5288826) Carvacrol (PubChem CID: 10364) Cancer pain Monoterpene Carvacrol Hyperalgesia
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	The present study evaluated the carvacrol (CARV) effect on hyperalgesia and nociception induced by sarcoma 180 (S180) in mice. Carvacrol treatment (12.5–50mg/kgs.c.) once daily for 15days was started 24h after injection of the sarcoma cells in the hind paw (s.c.). Mice were evaluated for mechanical sensitivity (von Frey), spontaneous and palpation-induced nociception, limb use and tumor growth on alternate days. CARV effects on the central nervous system were evaluated through immunofluorescence for Fos protein. Molecular docking studies also were performed to evaluate intermolecular interactions of the carvacrol and muscimol, as ligands of interleukin-10 and GABAA receptors. CARV was able to significantly reduce mechanical hyperalgesia and spontaneous and palpation-induced nociception, improve use paw, decrease the number of positively marked neurons in lumbar spinal cord and activate periaqueductal gray, nucleus raphe magnus and locus coeruleus. CARV also caused significant decreased tumor growth. Docking studies showed favorable interaction overlay of the CARV with IL-10 and GABAA. Together, these results demonstrated that CARV may be an interesting option for the development of new analgesic drugs for the management of cancer pain. [Display omitted]
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	0024-3205 1879-0631
DOI:	10.1016/j.lfs.2014.08.020